|Bid||8.65 x N/A|
|Ask||8.85 x N/A|
|Day's Range||8.75 - 8.75|
|52 Week Range||6.85 - 26.40|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for O23.BE
Earlier today, ZimVie released financial results for the quarter ended September 30, 2022. Before we begin, I'd like to remind you that management will make comments during the call that include forward-looking statements.
Third party net sales of $213.3 millionNet income of $0.8 million; net income margin of 0.4%; adjusted net income of $12.9 million Diluted EPS of $0.03; adjusted diluted EPS of $0.49Adjusted EBITDA of $29.4 million; adjusted EBITDA margin of 13.8% Cash and cash equivalents of $116.0 million at September 30, 2022Reaffirming full-year 2022 guidance for third party net sales, adjusted EBITDA margin, and adjusted EPS WESTMINSTER, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc.
Newest innovation in ZimVie’s digital dentistry platform is designed for immediacy and peri-implant healthWESTMINSTER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced the launch of the TSX Implant in the United States, the latest innovation in the company’s platform of surgical, restorative, and digital dentistry solutions. TSX Implants are designed for immediate extraction and loading protocols a